Lefroy D C, Crake T, Uren N G, Davies G J, Maseri A
Department of Medicine (Cardiology), Hammersmith Hospital, London, UK.
Circulation. 1993 Jul;88(1):43-54. doi: 10.1161/01.cir.88.1.43.
NG-Monomethyl-L-arginine (L-NMMA), a specific inhibitor of nitric oxide synthesis, was used to determine the effects of inhibition of nitric oxide synthesis in the human coronary circulation.
Twelve patients (mean age, 52 +/- 2 years) with normal epicardial coronary arteries were studied. The surface ECG, systemic blood pressure, and coronary venous oxygen saturation (coronary SvO2), an index of coronary blood flow, were monitored continuously. Coronary artery diameter was measured by quantitative arteriography. L-NMMA was given as intracoronary infusions at 2 mL/min via the diagnostic arteriography catheter. In two patients, low doses (0.01 to 5 mumol/min) of L-NMMA were infused into the nondominant right coronary artery. There was no evidence of ischemia in these patients, who were not included in the final analysis. In 10 patients, higher doses of L-NMMA (4, 10, and 25 mumol/min, each for 5 minutes) were infused into the left coronary artery. In six patients, incremental doses of acetylcholine were infused (1, 10, and 100 nmol/min, each for 3 minutes) before and after the L-NMMA infusion. Finally, in all patients, sodium nitroprusside, a nitric oxide donor, was infused. No patient developed myocardial ischemia. The heart rate and systemic blood pressure remained unchanged throughout the infusions. L-NMMA (25 mumol/min), compared with the control saline infusion, caused a significant reduction in distal (-5.9 +/- 2.1%, P = 0.021) but not proximal left anterior descending coronary artery (LAD) diameter and a fall in coronary SvO2 from 37.5 +/- 2.8% to 34.3 +/- 2.8% (P = 0.019). Sodium nitroprusside dilated the proximal (17.8 +/- 6.9%, P = 0.033) and distal (24.5 +/- 6.5%, P = 0.006) LAD and increased the coronary SvO2 to 61.6 +/- 5.0% (P = 0.0002). Acetylcholine caused significant dilatation of the distal (13.8 +/- 5.4%, P = 0.049) but not proximal LAD and a significant increase in coronary SvO2 from 36.5 +/- 3.5% to 59.2 +/- 2.8% (P < 0.0001). After L-NMMA, acetylcholine-induced dilatation of the distal LAD was abolished, but the rise in coronary SvO2 was unchanged.
Inhibition of nitric oxide synthesis in the human coronary circulation caused a decrease in basal distal LAD diameter and basal coronary blood flow assessed by coronary SvO2, indicating that there is a small basal release of nitric oxide in the distal epicardial coronary arteries and resistive vessels. Distal epicardial coronary artery dilatation in response to acetylcholine is nitric oxide dependent, but coronary resistive vessel dilatation is not.
NG-单甲基-L-精氨酸(L-NMMA)是一氧化氮合成的特异性抑制剂,被用于确定抑制一氧化氮合成对人体冠状动脉循环的影响。
对12例(平均年龄52±2岁)心外膜冠状动脉正常的患者进行了研究。持续监测体表心电图、体循环血压以及作为冠状动脉血流指标的冠状静脉血氧饱和度(冠状SvO2)。通过定量血管造影测量冠状动脉直径。通过诊断性血管造影导管以2 mL/分钟的速度向冠状动脉内输注L-NMMA。在2例患者中,将低剂量(0.01至5 μmol/分钟)的L-NMMA注入非优势右冠状动脉。这些患者未出现缺血迹象,未纳入最终分析。在10例患者中,将较高剂量的L-NMMA(4、10和25 μmol/分钟,各持续5分钟)注入左冠状动脉。在6例患者中,在输注L-NMMA前后分别注入递增剂量的乙酰胆碱(1、10和100 nmol/分钟,各持续3分钟)。最后,对所有患者注入一氧化氮供体硝普钠。没有患者发生心肌缺血。在整个输注过程中,心率和体循环血压保持不变。与输注对照生理盐水相比,L-NMMA(25 μmol/分钟)使左前降支冠状动脉(LAD)远端直径显著减小(-5.9±2.1%,P = 0.021),但近端未减小,并且冠状SvO2从37.5±2.8%降至34.3±2.8%(P = 0.019)。硝普钠使LAD近端(17.8±6.9%,P = 0.033)和远端(24.5±6.5%,P = 0.006)扩张,并使冠状SvO2增加至61.6±5.0%(P = 0.0002)。乙酰胆碱使LAD远端显著扩张(13.8±5.4%,P = 0.049),但近端未扩张,并且冠状SvO2从36.5±3.5%显著增加至59.2±2.8%(P < 0.0001)。注入L-NMMA后,乙酰胆碱诱导的LAD远端扩张被消除,但冠状SvO2的升高未改变。
抑制人体冠状动脉循环中的一氧化氮合成导致LAD远端基础直径减小以及通过冠状SvO2评估的基础冠状动脉血流减少,表明在心外膜冠状动脉远端和阻力血管中存在少量一氧化氮基础释放。乙酰胆碱引起的心外膜冠状动脉远端扩张依赖于一氧化氮,但冠状动脉阻力血管扩张并非如此。